Trials / Completed
CompletedNCT02213289
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | Trastuzumab |
| DRUG | ABT-806 | ABT-806 |
| DRUG | Bemarituzumab | Bemarituzumab |
| DRUG | Ramucirumab | Ramucirumab |
| DRUG | Nivolumab | Nivolumab |
| DRUG | Standard cytotherapy | FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line) |
Timeline
- Start date
- 2015-01-20
- Primary completion
- 2020-02-01
- Completion
- 2020-08-20
- First posted
- 2014-08-11
- Last updated
- 2021-04-08
- Results posted
- 2021-04-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02213289. Inclusion in this directory is not an endorsement.